Passage Bio Inc (PASG) Stock Analysis

Passage Bio Inc (PASG) is a publicly traded company in the HEALTHCARE sector. It trades at $4.57, carries a market capitalization of $16.06M. This page summarizes the public market data, fundamentals, and frequently asked questions for PASG, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Price: $4.57
Market Cap: $16.06M
EPS: $-12.54
52-Week High: $20.00
52-Week Low: $3.29

Market Sentiment

Passage Bio Inc currently has a Bullish sentiment score of 0.34.

About Passage Bio Inc

Passage Bio, Inc. is a leading biotechnology firm dedicated to pioneering gene therapies targeting rare monogenic disorders of the central nervous system. Based in Philadelphia, Pennsylvania, the company utilizes its proprietary adeno-associated virus (AAV) delivery platform to develop groundbreaking treatments that address critical unmet needs in neurology. With a comprehensive pipeline and strategic partnerships, Passage Bio is positioned to significantly influence the evolving landscape of...

GNG Research Analysis

GNG Research scores Passage Bio Inc (PASG) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for PASG.

Frequently Asked Questions

Does PASG pay dividends?

Passage Bio Inc (PASG) does not currently pay a regular dividend.

What is PASG's market cap?

Passage Bio Inc (PASG) has a market capitalization of $16.06M with a current stock price of $4.57.